No Data
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
Research pharmaceuticals, Punch industry, etc. [List of stock material from the newspaper]
*Kaken Pharmaceutical <4521> aims to expand sales rights and promote wound care materials from Sanyo Chemicals (Nikkan Kogyo page 3) - ○ * Punch Industry <6165> Misumi G Headquarters invests 1.2 billion yen, promoting domestic mutual supply (Nikkan Kogyo page 3) - ○ * Hitachi <6501> Hitachi Energy invests 37 billion yen in India, increasing transformer production (Nikkan Kogyo page 4) - ○ * Nissan <7201> Business efficiency through vehicle data, starting services for corporations (Nikkan Kogyo page 9) - ○ * Kyokuto Kai <7226> Completely redesigned garbage trucks, improving loading efficiency (Nikkan Giko)
Kaken Pharmaceutical To Go Ex-Dividend On September 27th, 2024 With 75 JPY Dividend Per Share And 40 JPY Special Dividend Per Share
September 26th (Japan Standard Time) - $Kaken Pharmaceutical(4521.JP)$ is trading ex-dividend on September 27th, 2024.Shareholders of record on September 30th, 2024 will receive 75 JPY dividend per
Fanpep Research Memo (4): Additional trials for the treatment of skin ulcers and the start of phase 1 clinical trials for pollen allergy vaccine have been newly decided.
■ Fanpep <4881> Major Development Pipeline Trends The company's development pipeline includes "SR-0379," which targets skin ulcers, as well as "FPP003," which targets psoriasis and ankylosing spondylitis developed using antibody-induced peptide technology. "FPP004X" for pollen allergy and "FPP005" for psoriasis are also among the 4 products. In addition, the company has several other development candidates. As for new progress in 2024, in March, it collaborated with Shionogi Pharmaceuticals to [rest of the text is truncated]
List of conversion stocks [List of conversion stocks for parabolic signals]
Buy conversion stock list market Code Stock name Closing price SAR Tokyo Prime ＜1766＞ Tobu Construction 11740 10550＜1887＞ Nihon Kokudo Kaihatsu 494 477＜2266＞ Rokko Butter 1498 1410＜2294＞ Kakiyasu Mototen 2640 2554＜2378＞ Renaissance 1066 1034＜2670＞
Honda's operating profit in Q1 increased by 22.9%, reaching 484.7 billion yen.
Honda (7267) announced its first quarter results for the fiscal year ending in March 2025, with sales revenue of 5 trillion 404.858 billion yen, a year-on-year increase of 16.9%, and operating profit of 484.705 billion yen, a year-on-year increase of 22.9%. This exceeded the consensus (around 473 billion yen). The global number of passenger carried increased mainly in India and Brazil in the motorcycle business. The strong sales of hybrid models also continued in the four-wheel business. [Positive evaluation] 5858 STG, 79.
No Data
No Data